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Abstract: Gene therapy using integrating retroviral vectors has proven its effectiveness in 
several  clinical  trials  for  the  treatment  of  inherited  diseases  and  cancer.  However,  
vector-mediated  adverse  events  related  to  insertional  mutagenesis  were  also  observed, 
emphasizing the need for safer therapeutic vectors. Paradoxically, alpharetroviruses, originally 
discovered as cancer-causing agents, have a more random and potentially safer integration 
pattern  compared  to  gammaretro-  and  lentiviruses.  In  this  review,  we  provide  a  short 
overview of the history of alpharetroviruses and explain how they can be converted into 
state-of-the-art gene delivery tools with improved safety features. We discuss development of 
alpharetroviral vectors in compliance with regulatory requirements for clinical translation, 
and provide an outlook on possible future gene therapy applications. Taken together, this 
review is a broad overview of alpharetroviral vectors spanning the bridge from their parental 
virus discovery to their potential applicability in clinical settings. 
Keywords:  retrovirology;  alpharetroviral  vector;  gene  therapy;  clinical  translation; 
regulatory requirements; vector safety 
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1. Introduction 
Human gene therapy incorporating genome engineering to enhance cell functions has the potential to 
cure numerous life-threatening diseases, including severe combined immunodeficiencies and cancer. 
The evolutionary optimized ability to stably integrate DNA into cellular genomes makes retroviruses 
very attractive for permanent therapeutic cell modifications. During the last decades, retroviruses have 
been developed into valuable tools for human gene therapy with the focus on vectors derived from 
gammaretroviruses and lentiviruses. However, retroviral vector integration into the target cell genome 
can cause insertional activation of cellular proto-oncogenes, potentially leading to serious adverse events 
such as leukemia. This adverse effect of retroviral vectors on cellular integrity is termed genotoxicity 
and can be influenced by several factors, such as vector design and integration target site selection.  
In  contrast  to  conventional  gammaretroviral  and  lentiviral  vectors,  alpharetroviral  vectors  have 
comparatively neutral integration target site preferences, hence alpharetroviral vectors might be less 
genotoxic and therefore of therapeutic value. In the present review, we highlight previous alpharetroviral 
vector discoveries as well as current developments and the potential of alpharetroviral applications for 
future human gene therapy strategies. 
2. History of (Alpha-) Retroviruses 
More than 100 years ago, Vilhelm Ellermann and Oluf Bang demonstrated that cell-free filtrates were 
able  to  transmit  leukemia  in  chickens  [1].  A  few  years  later,  Francis  Peyton  Rous  described  
the cell-free transmission of chicken sarcoma [2,3]. These groundbreaking discoveries indicated that 
cancer could be caused by viruses, a novel paradigm which was not widely accepted at that time.  
In fact, researchers supporting the concept of viruses causing cancer were said to either have “holes in 
their  heads  or  holes  in  their  filters”  [4].  Nevertheless,  especially  the  Rous  sarcoma  virus  (RSV),  
a  paradigmatic  species  of  the  alpharetroviral  genus,  played  an  important  role  in  the  history  of 
retrovirology and in cancer research (Figure 1). 
 
Figure 1. Timeline of hallmark events in the history of retrovirology. 
One important development made possible by the discovery of RSV was the focus assay, which 
provided the technical basis for studying viral infection on single viral particle and single cell levels and 
thus  enabled  researchers  to  investigate  the  molecular  details  of  retroviral  replication  [5].  It  was 
discovered that the RSV genome consisted of RNA [6], but that RSV infection required cellular DNA 
for replication [7]. This apparent contradiction was resolved with the provirus hypothesis published by Viruses 2014, 6  4813 
 
 
Howard  Temin  in  1964:  “The  results  presented  here  with  RSV  can  be  most  simply  explained  by  
the  following  model:  virus  enters  a  cell  and  directs  formation  of  a  DNA  containing  the  genetic 
information of the virus. This new DNA, the provirus […], then acts as a template for formation of new 
nucleic acid, RNA, for the virion” [8]. This hypothesis, independently proposed by Jan Svoboda and 
coworkers  [9],  was  initially  met  with  skepticism,  but  eventually  became  widely  accepted  upon 
identification of reverse transcriptase [10,11]. Many additional discoveries concerning the retroviral life 
cycle soon followed. However, the mechanism of RSV-induced cancer remained an unsettled issue until 
1976, when molecular hybridization studies by Harold E. Varmus, J. Michael Bishop and coworkers 
revealed that, “[…] part or all of the transforming gene(s) […] was derived from the chicken genome 
or a species closely related to chicken […]” [12]. The transforming gene transferred by RSV was then 
identified as the SRC proto-oncogene, and soon followed by the discovery of additional oncogenes 
transferred by other retroviral species. Discovery of the cellular origin of viral oncogenes drastically 
changed the perspective of cancer research and immensely contributed to the understanding of cancer 
development. However, the transfer of proto-oncogenes was not the only mechanism through which 
retroviruses could cause cancer. In a process called insertional transformation, the retroviral promoter 
elements were shown to increase expression of cellular proto-oncogenes, such as MYC, thereby causing 
neoplasms,  albeit  as  rare  events  and  with  much  longer  latencies  than  the  acute  transforming  
oncogene-transferring counterparts [13,14]. The genotoxic effect of retroviruses, first described in 1981, 
led to a severe setback in human gene therapy more than a decade later. Consequently, the mechanisms 
of insertional genotoxicity have been intensely studied and retroviral vector designs have been markedly 
improved, thus increasing the safety of human gene therapy.  
3. From the Virus to the Vector 
3.1. Taking a Different Perspective: Retroviruses for Human Gene Therapy 
The discovery of viral transfer of genes other than those required for viral replication [12] served as 
a paradigm for the development of human gene therapy vectors. With the increasing knowledge of  
the  genetic  origin  of  many  diseases  in  the  genomics  era,  researchers  envisioned  that  by  inserting  
a corrected version of a defective gene into a patient’s genome, a permanent cure could be achieved on 
a molecular basis. Gene therapy aims at curing life-threatening diseases, such as severe combined 
immunodeficiencies  and  cancer  by  exploiting  the  retroviral  life  cycle  for  the  transfer  of  such  
therapeutic transgenes. 
While aforementioned historical discoveries were made with avian-infectious alpharetroviral vectors, 
researchers working on gene therapy initially exploited gammaretroviral vectors derived from MLV 
(murine  leukemia  virus),  which  naturally  replicates  in  mice.  From  a  safety  perspective,  
the availability of cell lines for the production of replication-defective retroviruses in 1983 marked  
an important step towards the development of retroviral vectors for human gene therapy [15]. Soon 
thereafter, pioneering studies in mice proved the concept of transferring genes into hematopoietic stem 
cells, albeit with low levels of gene transfer and gene expression [16,17]. During the next two decades, 
retroviral vectors were markedly improved with greater focus on vectors derived from gammaretroviruses 
(MLV)  and  lentiviruses  (human  immunodeficiency  virus-1,  HIV-1).  Clinical  benefit  to  previously Viruses 2014, 6  4814 
 
 
terminally ill patients was demonstrated in several preclinical studies and clinical trials have employed 
these vectors to treat primary immunodeficiencies, such as severe combined immunodeficiency (SCID) 
and chronic granulomatous disease (CGD). However, despite therapeutic benefits, some of these patients 
suffered from severe adverse events due to clonal expansion of transduced cells, eventually leading to 
myelodysplastic syndromes and/or leukemias [18]. Furthermore, the clinical success in the CGD trial 
was hampered by the occurrence of vector silencing, which resulted in only a transient benefit [19,20]. 
These adverse events led to the temporary postponement of many gene therapy clinical trials. Intensive 
investigations revealed that they resulted from genotoxic integrations of retroviral vectors in the genome, 
leading to upregulation of cellular proto-oncogenes, such as LMO2 and MDS1-EVI1 [20–24]. First 
described for replicating retroviruses more than a decade earlier, the risk of insertional proto-oncogene 
activation had initially been anticipated to be low for replication-defective retroviral vectors. However, 
insertional activation still occurred in clinical trials, thus raising the urgent question of how to improve 
the safety of retroviral gene therapy.  
3.2. Genotoxicity of Retroviral Vectors 
Identification  of  the  mechanisms  and  reduction  of  underlying  genotoxicity  have  become  major 
objectives of the field of human gene therapy. In general, retroviral vector genotoxicity is due to 
upregulation  of  cellular  proto-oncogene  expression  and  can  theoretically  be  caused  by  several 
mechanisms, such as (i) promoter insertion; (ii) promoter activation and (iii) gene transcript truncation 
(Figure 2). 
(i) The genotoxic mechanism of promoter insertion describes the insertion of promoter sequences 
directly  upstream  of  cellular  transcription  units,  thereby  adversely  influencing  their  expression  
(Figure 2i). This can either be mediated by read-through transcription from the inserted promoter into 
the adjacent gene or by a combination of read-through transcription and splicing events involving vector 
and cellular splice sites. In 1981, promoter insertion became the first described mechanism of insertional 
transformation for replicating alpharetroviruses and caused neoplastic transformation in birds. In the 
reported cases, the viral promoter, which resides in the 5' and 3' long terminal repeats (LTRs) of the 
retrovirus, caused read-through transcription into the cellular MYC proto-oncogene and was detected by 
the presence of virus-MYC fusion transcripts [13,14]. In addition to the overexpression of adjacent genes, 
promoter insertion can also lead to oncogene capture by replication-competent retroviral vectors and 
thus to the development of acute transforming viruses. These viruses have an enormous genotoxic 
potential as oncogene expression occurs irrespective of their integration sites. However, while promoter 
insertion can be induced by any retroviral vector harboring promoter elements, oncogene capture is a 
very rare event and is restricted to replication-competent vectors. Additionally, in contrast to RSV, most 
acute transforming viruses become replication-defective, as they lose part of their viral coding sequences 
and thus require helper viruses for infectious viral particle formation. 
(ii)  In  most  clinical  trials,  which  used  replication-defective  gammaretroviral  vectors,  promoter 
activation was identified as the primary cause of transformation (Figure 2ii). Here, the powerful enhancer 
in the gammaretroviral LTR most likely caused upregulated expression of cellular proto-oncogenes, such 
as LMO2 or MDS1-EVI1 [20–24]. While the mechanism of promoter insertion is restricted to upstream 
and in sense-oriented integrations of the retroviral vector adjacent to the affected cellular transcription Viruses 2014, 6  4815 
 
 
unit, enhancer-mediated promoter activation can occur at different orientations and loci up to several 
hundred kilobases from the insertion site [25,26]. 
 
Figure 2. Genotoxicity mechanisms. (i) Promoter insertion upstream and in sense to cellular 
transcription units can lead to read-through transcription into adjacent cellular genes, either 
from the internal promoter or from the long terminal repeat (LTR) as indicated by the arrows. 
If  splice  acceptor  (SA)  and  donor  (SD)  sites  are  present,  promoter  insertion  can  be 
accompanied by splice events; (ii) promoter activation is mediated by enhancer-interactions 
by respective elements in the internal promoter or in the LTR with  cellular promoters;  
(iii) gene transcript truncation can lead to shortened cellular transcripts, either lacking 3' (left 
example) or 5' sequences (right example). 
(iii) There is increasing evidence that gene transcript truncation is also a safety concern (Figure 2iii). 
In contrast to promoter insertion, gene transcript truncation is caused by intragenic retroviral vector 
integrations. These intragenic integrations frequently occur in intronic regions, involve aberrant splicing 
events and result in a loss of either 5' or 3' sequences of cellular genes. When transcription initiates from 
an inserted promoter, 5' sequences of the affected cellular gene are lost (Figure 2iii; right example). In 
contrast, when transcription is initiated from a cellular promoter followed by read-through into the 
retroviral vector, loss of 3' sequences can be caused by premature polyadenylation at polyadenylation 
sites introduced within the vector (Figure 2iii; left example). In several murine studies using lentiviral 
vectors, gene transcript truncations of 5' or 3' sequences led to leukemia development by either removal 
of  regulatory  regions  of  proto-oncogenes  [27]  or  by  downregulation  of  full-length  transcripts  of 
supposedly haploinsufficient tumor suppressor genes [28]. Functional consequences of gene transcript 
truncation  were  also  demonstrated  in  a  clinical  trial  involving  one  patient  suffering  from  
β-thalassemia [29]. After lentiviral β-globin gene transfer, this patient showed therapeutic benefit largely Viruses 2014, 6  4816 
 
 
attributed to a dominant clone, in which intragenic vector integration in HMGA2 had occurred. This 
insertion  led  to  a  3'  gene  transcript  truncation,  rendering  the  shortened  mRNA  insensitive  to  
microRNA-mediated downregulation, thus upregulating HMGA2, which led to clonal expansion. While 
this benign clonal expansion has not resulted in a serious adverse event to date, and is actually associated 
with clinical benefit, it clearly demonstrates the potency of gene transcript truncation to contribute to 
clonal imbalance in a clinical setting. 
Promoter insertion, promoter activation and gene transcript truncation are the three most prevalent 
mechanisms of retroviral vector genotoxicity described to date. While these mechanisms have been 
described individually for the sake of clarity, insertional mutagenic events show a higher layer of 
complexity. For example, a single integration may affect more than one gene and induce transcriptional 
deregulation by more than one mechanism simultaneously [30]. Importantly, our current understanding 
of genotoxicity mechanisms allows several prevention strategies to be envisioned. Since insertional 
deregulation  of  cellular  transcription  is  dependent  on  the  presence  of  strong  promoter/enhancer 
sequences and splice sites, optimized vector design should omit these elements. In addition, integration 
target sites influence genotoxicity, with potentially detrimental integrations occurring near or within 
genes, especially proto-oncogenes and tumor suppressor genes. In this regard, genome-wide studies of 
retroviral  DNA  integration  have  elucidated  distinct  integration  target  site  preferences  for  different 
retroviral vectors. While gammaretroviral vectors preferentially integrate in the proximity of transcription 
start sites, CpG islands, and genes with implications in cancer, lentiviral vectors tend to integrate within 
transcription units of actively transcribed genes [27,31–41]. These integration target site preferences are 
influenced by retrovirus-specific interactions of the retroviral integrase with cellular tethering factors, 
such as lens-epithelium-derived growth factor/p75 (LEDGF) in the lentiviral [42–46] and bromodomain 
and extraterminal domain (BET) proteins in the gammaretroviral context [47–49]. These tethering 
factors direct retroviral integrations to specific regions in the genome and thus largely contribute to 
integration target site preferences. There have been attempts to modify retroviral vectors and/or their 
tethering factors with the aim to obtain potentially safer integration characteristics [50–56]. However, 
some of these modifications suffered from reduced gene transfer efficacy or incomplete redirection of 
integration site preference and clinical applicability remains to be shown. Importantly, in contrast to 
gammaretroviral  and  lentiviral  vectors,  alpharetroviral  vectors  have  a relatively  neutral  integration 
spectrum [57–61]. It is currently unknown whether alpharetroviral integration follows a pattern yet to 
be identified or if it occurs independently from tethering factors. Nevertheless, the comparatively neutral 
integration pattern of alpharetroviral vectors renders them less genotoxic [59–61] and thus increases their 
therapeutic value for future human gene therapy. 
3.3. Retroviral Vector Safety Criteria 
In order to comply with latest safety standards, retroviral vectors need to fulfill the following criteria: 
(i) replication-incompetence; (ii) low genotoxicity and (iii) low immunogenicity. 
(i) Replication-incompetence is of paramount importance, as uncontrolled virus spread represents an 
enormous safety hazard not only in terms of potential oncogene capture, but also in terms of high vector 
doses. Patients undergoing hematopoietic gene therapy may be immunocompromised and thus unable 
to fight virus spread, which can lead to unpredictably high vector copy numbers and transductions of Viruses 2014, 6  4817 
 
 
cells other than the initial target cells. Replication competent retrovirus (RCR) formation led to the 
development  of  T-lymphocyte  neoplasms  in  a  rhesus  model  of  stem  cell  transplantation  using 
gammaretroviral vectors. The resulting lymphoma cells contained very high vector copy numbers [62], 
clearly demonstrating that uncontrolled vector spread is associated with unpredictably high vector dose, 
thus contributing to genotoxicity. Furthermore, replication selects for viruses with smaller genomes, 
eventually resulting in viruses lacking part or all of their genomic information. These viral integrants are 
not only unable to confer any therapeutic effect, but also increase the genotoxic risks, as described for 
open reading frame-defective retroviral vectors [63]. The generation of replication-defective retroviruses 
can be achieved by using the split-packaging system for viral particle production. In this system, the 
retroviral genome is split into multiple sequence components, either provided by different plasmids 
(transient production) or integrated into different genomic loci (stable production). Irrespective of the 
production method used, these sequence components either contain the genetic information of the 
retroviral vector or of viral proteins needed for particle production. Importantly, only the retroviral vector 
sequence harbors the packaging signal and sequences required for reverse transcription and integration. 
Thus,  the  genetic  information  of  the  trans-complementing  sequences,  i.e.,  for  structural  proteins, 
replication enzymes and envelopes, will not be selectively incorporated into retroviral particles, nor will 
they be reverse transcribed and integrated into the target cell genome. As a consequence, transduced 
target  cells  cannot  produce  progeny  viral  particles  due  to  the  lack  of  expression  of  retroviral  
proteins [64–66]. The split-packaging design does not only avoid virus replication, but also creates space 
for large transgene cassettes due to the removal of viral coding sequences from the genomic message. 
To  prevent  de  novo  RCR  formation,  it  is  advisable  to  avoid  sequence  homologies  between  the  
trans-complementing and retroviral vector sequences. Splitting the genomic information needed for viral 
protein expression into more than two components further decreases the likelihood of RCR formation. 
(ii) Especially the occurrence of serious adverse events in human gene therapy clinical trials has 
underscored the urgent need for retroviral vectors with low genotoxicity. Intensive research efforts have 
demonstrated  that  in  addition  to  the  integration  pattern,  strong  promoter  and  enhancer  elements 
profoundly affect genotoxicity. Thus, to further “disarm” retroviruses, viral promoter and enhancer 
elements, which reside in the unique three (U3) regions of viral LTRs, should be removed [67,68]. Since 
these transcriptional elements drive the expression of the viral genomic information, they are usually 
very potent and can modulate expression of cellular genes. This can lead to deleterious insertional 
upregulation of proto-oncogenes by promoter insertion or activation. Most gene therapeutic applications 
require physiologic transgene expression levels, which can be achieved by removing viral promoter and 
enhancer elements by introducing a so-called self-inactivation (SIN) deletion and inserting an internal 
promoter of choice. This not only reduces the vector’s genotoxicity [27,69,70], but also its potential 
phenotoxicity, which can be caused by the ectopic overexpression of transgenes potentially interfering 
with cell function and proliferation [71]. Due to the absence of full-length genomic RNA in transduced 
cells, SIN vectors have the additional advantage of further diminishing the likelihood of RCR formation. 
Another safety measure to decrease the risk of insertional deregulation of cellular gene expression is the 
removal of splice sites from the vector, as these sites can lead to aberrant splicing events and are 
frequently involved in gene transcript truncations [27–29]. Interestingly, all of the aforementioned vector 
developments and their effects on genotoxicity were recapitulated in an extensive in vivo study in a 
tumor prone mouse model. In this model, it was shown that oncogene activation by promoter insertion Viruses 2014, 6  4818 
 
 
had the highest genotoxic potential, leading to early onset of vector-induced transformations and was 
associated with the use of primitive vector configurations, which still contained intact LTRs. Introducing 
the SIN deletion and strong internal promoters frequently led to enhancer-mediated promoter activation. 
In contrast, use of weaker internal promoters in the SIN context significantly reduced the genotoxic 
potential, with a shift in the most prevalent genotoxicity mechanism from promoter activation to gene 
transcript truncation. Further reduction in genotoxicity was observed for advanced retroviral SIN vectors 
with weak internal promoters and insulators. However, these vectors were still capable of inducing 
cellular transformation via gene transcript truncation, thus clearly arguing for the additional removal of 
splice sites [63]. 
(iii) Retroviral vector immunogenicity can be provoked by expression of viral or therapeutic proteins 
in transduced cells leading to humoral and cellular immune responses against transgene- and/or retroviral 
vector-derived  epitopes  [72,73].  Thus,  immunogenicity  can  hamper  the  long-term  presence  of  
gene-modified  cells,  which  is  critical  for  most  gene  therapy  approaches.  Therefore,  even  though 
retroviral vector-mediated immunogenicity has not led to serious adverse events to date, it still deserves 
attention. Consequently, viral coding sequences should be completely eliminated from the vector, when 
designing the split-packaging system. 
3.4. Alpharetroviral Vector Developments 
Compliance with the aforementioned retroviral safety criteria is necessary in order to take advantage of 
the comparatively neutral alpharetroviral integration pattern for clinical applications. The most widely 
used alpharetroviral vector system is the RCAS (replication-competent avian leukosis virus LTR with a 
splice acceptor) system [74,75]. RCAS is based on RSV, in which the captured SRC oncogene has been 
exchanged by a unique restriction site, via which a transgene of interest can be inserted. The original 
RCAS vector is replication-competent in avian cells (its natural host) and expresses the transgene from 
a spliced message. Due to its replication-competence, high viral titers can be achieved in avian cells. In 
order to transduce mammalian cells, the alpharetroviral envelope glycoprotein was replaced by envelope 
glycoproteins  derived  from  other  retroviruses  in  a  process  called  pseudotyping. While  this allows 
transduction of mammalian cells, it generally precludes alpharetroviral replication in mammalian cells 
due to several blocks in the life cycle (as reviewed by [76]). Nevertheless, for clinical applications, the 
potential for viral replication/mobilization should be entirely eliminated, and thus pseudotyped RCAS 
vectors are unlikely to fulfill current clinical safety criteria. However, they are extremely useful for 
nonclinical applications and have been successfully used to transduce rhesus macaque hematopoietic 
stem and progenitor cells. After transplantation, long-term polyclonal engraftment with gene marking in 
myeloid  and  lymphoid  lineages  was  observed,  thus  clearly  underlining  the  clinical  relevance  of 
alpharetroviral vectors [77]. RCAS-derived vectors lacking the envelope gene have been designed to 
facilitate the generation of variably pseudotyped alpharetroviral vectors. Pseudotyped alpharetroviral 
vectors  can  be  produced  to  allow  the  transduction  of  mammalian  cells  by  providing  the  genetic 
information for the envelope in trans in packaging cells [78,79]. Since the vectors lacking the envelope 
gene do not contain all the information needed for viral replication, these vectors can be considered 
replication-defective even in avian cells. However, they lack the advanced split-packaging design and Viruses 2014, 6  4819 
 
 
the SIN deletion, which are present in state-of-the-art gammaretroviral and lentiviral vectors and which 
are required for clinical applications [80–82]. 
Aiming  for  a  clinically  applicable  alpharetroviral  vector  system,  we  designed  an  advanced  
split-packaging  design  completely  avoiding  sequence  overlaps  between  the  constructs  expressing 
retroviral  proteins  in  trans  and  the  actual  genomic  message  to  be  packaged  [83]  (Figure  3),  thus 
minimizing the risk of RCR formation. The resulting transfer vector is also devoid of splice sites as  
the alpharetroviral splice donor is within the gag reading frame, further preventing potentially genotoxic 
splicing events. This is in contrast to gammaretroviral and lentiviral vectors, which still contain retroviral 
splice sites. Using the alpharetroviral split-packaging system, we successfully generated alpharetroviral 
particles from human 293T cells via transient plasmid transfection, albeit with low titers. However, 
codon-optimization  of  the  alpharetroviral  gag-pro/pol  sequence  for  human  tRNA  codon-usage 
preferences spared ~300 bp in the gag-pro/pol transition region required for ribosomal frameshifting 
(Figure 3), and drastically increased titers by several orders of magnitude (approx. 107 transducing units 
(TU)/mL) [83]. 
 
Figure  3.  Alpharetroviral  SIN  split-packaging  system.  Schematic  depiction  of  
the  alpharetroviral  split-packaging  system,  with  a  replication-competent  alpharetrovirus 
shown on top and the three respective split-packaging system components shown below. The 
viral  coding sequence  components are split  onto  two plasmids,  one  encoding  the viral 
envelope  (env)  and  one  encoding  the  gag-pro/pol  polyprotein.  The  latter  was  
codon-optimized,  sparing  approximately  300  bp  in  the  gag-pro/pol  transition  region  to 
ensure  proper  frameshifting.  The  vector  constitutes  the  third  component  of  the  
split-packaging system. An external promoter drives the expression of the RNA, which 
contains an internal transgene expression cassette, a packaging signal (Ψ), and R, U5 and U3 
regions, allowing for packaging, reverse transcription and integration. An alpharetroviral 
SIN vector was designed by removing transcriptional control elements from the U3 region 
(ΔU3) of the LTR. 
In a next step, we removed transcriptional control elements from the LTRs to generate alpharetroviral 
SIN vectors with reduced genotoxic potential and the ability to mediate physiologic transgene expression Viruses 2014, 6  4820 
 
 
levels via internal promoters (Figure 3). Initially, we deleted 159 nucleotides of the wild-type U3 region, 
preserving the terminal 3' and 5' U3 sequences to maintain integrase attachment and polyadenylation 
sites [83]. While we showed that this initial SIN design reduced U3 transcriptional activity to background 
levels, this vector still contained the TATA box, a core promoter element of retroviruses. To exclude 
potential transcription due to this promoter element, we generated a second generation SIN vector by 
deleting the TATA box [60]. Importantly, both SIN designs eliminated several enhancer elements from 
the U3 region, such as CAAT enhancers, Y box motifs, and CArG boxes [84], thus increasing retroviral 
vector genosafety [69,85,86] and avoiding interference with the regulation of the internal promoter. 
Using this latest generation of alpharetroviral SIN vectors, we and others demonstrated a comparatively 
neutral integration pattern in murine hematopoietic stem and progenitor cells, reduced genotoxicity in 
sensitive in vitro immortalization assays [60], and lack of aberrant splicing [87] compared to clinically 
used gammaretroviral and/or lentiviral SIN vectors. In more sophisticated integration site analyses in 
human  hematopoietic  stem  and  progenitor  cells,  alpharetroviral  vectors  exhibited  a  comparatively 
neutral integration pattern with regard to several annotated genomic features and potentially dangerous 
genomic loci, as well as with regard to epigenetically-defined functional genomic regions, such as 
enhancers (H3K4me1+) and promoters (H3K4me3+) when compared to gammaretroviral or transcribed 
gene bodies (H3K36me3) when compared to lentiviral vectors [61]. Finally, proof-of-principle was 
provided for the alpharetroviral genetic modification of hematopoietic stem and progenitor cells in  
mice [60], the modification of human T lymphocytes and NK cells (unpublished data), and phenotypic 
correction of X-linked CGD in a humanized mouse model [87]. 
In general, retroviral gene expression can be hampered by silencing, one of the cellular defense 
mechanisms against foreign DNA [88], leading to the downregulation of transgene expression. Silencing 
is mediated by cellular factors, which can recognize repressive elements on the vector, such as the 
retroviral primer binding site [89] or parts of the LTRs [90]. Silencing results in the formation of 
repressive  epigenetic  marks,  including  DNA  methylation  and  histone  deacetylation.  In  addition  to 
gammaretro- and lentiviral vectors (reviewed in [91]), silencing has also been described in the context 
of  alpharetroviral  vectors  [92–98].  It  can  generally  be  influenced  by  the  target  cell  species  [96],  
the  differentiation  status  of  the  cell  [99],  the  cell  type  [100]  and  the  position  of  the  integration  
site [101–103]. As alpharetroviral silencing has been reported to be more pronounced in mammalian 
than in avian cells [96], future modifications of alpharetroviral vectors should contain “antisilencing” 
modifications  to  ensure  sustained  therapeutic  transgene  expression.  Such  modifications  include  
the removal of repressive elements from the vector and/or the insertion of supporting transcriptional 
regulatory elements. To this effect, the removal of viral coding sequences (split-packaging design) and the 
removal of transcriptional elements (SIN design) might already have eliminated repressive elements 
from the vector. In addition, transgene expression in SIN vectors is independent from LTR-mediated 
transcription and has been reported to be less susceptible to silencing in the context of gammaretro- and 
lentiviral SIN vectors (reviewed in [91]). Nevertheless, future incorporation of supporting transcriptional 
regulatory  elements,  such  as  scaffold/matrix  attachment  regions,  insulators,  locus  control  regions, 
ubiquitous chromatin opening elements [104] or chimeric versions thereof [105], is likely to enhance the 
therapeutic potential of alpharetroviral SIN vectors [76,106,107]. 
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4. On the Road to Clinical Applicability: Production Perspectives of Alpharetroviral Vectors 
In the last decade, the number of gene therapy clinical trials using gammaretro- and lentiviral vectors 
for  stable  genome  modifications  has  almost  doubled  from  254  in  2004  to  498  in  2014. 
(http://www.abedia.com/wiley/; updated June 2014). Thus, there is an increasing demand for clinically 
applicable retroviral  vector batches partially  shifting the focus of successful  clinical translation to 
economic vector production.  
In general, retroviral vectors can be produced either transiently or stably. Both methodologies possess 
distinct advantages and disadvantages regarding establishment, flexibility, reproducibility, up-scaling 
possibilities and quality assurance. For transient production, all components  of the split-packaging 
system (the vector and the helper constructs encoding necessary viral proteins) are transiently delivered as 
plasmids  into  the  packaging  cells.  This  allows  for  flexible  exchange  of  vector  components.  
In contrast, the establishment of a stable production for clinical vectors is highly time-consuming and 
labor-intensive. Here, all components need to be stably integrated into the genome of the virus-producing 
packaging cell line followed by the identification of high-producer clones. Such clones usually display 
a high level of batch-to-batch product consistency, whereas transiently produced viral particles are 
subject to significant fluctuations [108,109]. Due to the obligatory delivery of good manufacturing 
practice  (GMP)-grade  plasmids,  up-scaling  of  the  transient  production  process  is  expensive  and 
technically demanding. Additionally, transiently produced vector batches for clinical application need 
to be purified from remaining plasmids to avoid uncontrolled plasmid delivery to the patient. Taken 
together, the viral vector generation via stable packaging cell lines is preferred from the regulatory, the 
production-related and therefore from the economical point of view. 
Irrespective  of  the  production  method,  the  formation  of  RCR  is  a  major  safety  concern.  RCR 
formation can result from recombination events between the vector and either the helper constructs or 
endogenous retroviruses [110] within the producer cell. Therefore, intensive screening for RCR is 
required for clinical vector batches, the producer cells as well as for treated patients [111]. In general, the 
likelihood  of  RCR-formation  is  lower  in  stable  packaging  cell  lines  compared  to  transient  vector 
production, because stable producer cells are not transfected with millions of plasmid molecules [112]. 
Regarding the probability of RCR formation, alpharetroviral vectors possess additional safety features 
compared to other retroviral vector platforms with a split-packaging design, as alpharetroviral vectors 
do not exhibit any sequence overlap with their helper constructs encoding alpha gag-pro/pol and the 
envelope glycoprotein (see Section 3.4). This is of importance, as an overlap of as little as 8 bp already 
increases  the  probability  of  recombination  events  and,  ultimately,  the  formation  of  RCR  [113]. 
Moreover,  alpharetroviruses  can  efficiently  infect  but  generally  not  replicate  in  mammalian  cells, 
probably due to various blocks in the retroviral life cycle [75,114] (as reviewed by [76]). Therefore, even 
in the improbable case of RCR-formation, the newly formed virus is not likely to propagate in subjects 
of human gene therapy trials. Of note, RCR-formation was never detected despite intensive PCR-based 
screening in the follow-up analysis of patients receiving retrovirally-modified cells [115]. 
Whereas a number of different stable packaging cell lines of murine and human origin are available 
for  gammaretroviral  vectors,  the  establishment  of  such  cell  lines  in  the  lentiviral  context  is  still 
challenging. Long-term expression of certain lentiviral packaging components (e.g., the protease) is Viruses 2014, 6  4822 
 
 
cytotoxic,  leading  to  silencing  and  loss  of  productivity  over  time  [112,116].  Therefore,  transient 
production of clinically applicable lentiviral vectors is currently the technology of choice.  
The first stable packing cell line (Isolde) for alpharetroviruses with an advanced split-packaging 
design was developed in 1990 by Cosset and colleagues [117]. Here, the RSV-derived viral genome was 
split onto three distinct plasmids with individual antibiotic resistance expression cassettes. To avoid 
packaging and replication of the helper constructs (encoding for alpha gag/pol and the natural envelope 
(subgroup A)), the packaging signal ψ as well as the 3'LTR- regions were deleted. All constructs were 
serially transfected into QT6 cells (a quail fibrosarcoma cell line) and selected via antibiotic treatment, 
yielding titers of up to 105 TU/mL. Although all constructs possessed shared homologous regions, 
formation of RCRs was not detected [117]. Because of a higher productivity [118], RCAS vectors and 
derivatives  have  usually  been  produced  in  DF-1  cells  [119],  an  untransformed  chicken  embryo 
fibroblast-derived  cell  line,  which  does  not  contain  endogenous  viruses  closely  related  to 
alpharetroviruses. After transient delivery of the replication-competent RCAS vector, spreading of the 
vector throughout the DF-1 culture occurs resulting in high titer retroviral batches. For RCAS vectors 
harboring transgenes ≤2.8 kb, titers of >107 infectious units/mL were produced [114]. As mentioned 
above, the potentially replicative nature of the RCAS vector and the presence of gag/pol and env exclude 
this technology for human gene therapy approaches. Therefore, we established a replication-defective 
alpharetroviral  SIN  vector  platform,  derived  from  the  RCASBP-Y  DV  vector  [120],  for  
clinical applications. 
Using this vector platform, we transiently produced alpharetroviral SIN vector batches with titers in 
the range of 107 TU/mL in human cells (293T) after optimization of the alpharetroviral gag-pro/pol 
nucleotide sequence for human tRNA codon usage [83] (see Section 3.4). The internal reporter gene 
expression cassette used in this experiment was relatively small with a size of ~1.8 kb. However, using 
the optimized gag-pro/pol we also successfully generated alpharetroviral particles with internal cassettes 
of ~5.8 kb at reasonable titers (106 TU/mL). While the theoretical packaging capacity of alpharetroviral 
vectors is approx. 8.8 kb [121], which would allow incorporation of large therapeutic transgene cassettes, 
the actual production feasibility needs to be determined empirically, as the nature of the transgene can 
have a greater impact than the sheer sequence length [122]. 
With the codon-optimized alpharetroviral gag-pro/pol construct and the same internal reporter gene 
expression cassette used for transient transfection, we established stable, monoclonal alpharetroviral SIN 
packaging cell lines derived from human 293 cells (DSMZ, ACC 305) showing sustained productivity 
over at least six months (unpublished data). The titers varied depending on the glycoprotein used for 
pseudotyping  and  ranged  from  106  TU/mL  (pseudotyped  with  RD114/TR  [123])  to  107  TU/mL 
(pseudotyped with ecotropic env). For future stable and economic alpharetroviral vector production, the 
capacity to culture 293 cells in suspension could greatly simplify the production process and thereby 
reduce the production costs [124]. Furthermore, suspension-growing producer cells lack extracellular 
matrix  proteins,  predominantly  proteoglycans,  which  have  been  shown  to  inhibit  retroviral  
transduction [125]. In addition to high titers of alpharetroviral vectors, another advantage of using human 
cells for viral particle production is the potentially reduced immunogenicity of the retroviral particles. 
Since the viral membrane envelope is derived from the producer cell, all incorporated membrane proteins 
have been processed in the packaging cell. Even though cellular proteins are only efficiently incorporated 
into viral particles when expressed at high densities at the plasma membrane [126], the possibility of  Viruses 2014, 6  4823 
 
 
cross-species transfer of membrane proteins should be excluded. Furthermore, viral proteins produced 
in  human  cells  possess  human  glycosylation  profiles  and are  therefore  less  immunogenic.  This  is 
especially important for in vivo gene therapy approaches [127], in which the viral particles are directly 
applied to the patient and, thus, are directly exposed to the patient`s immune system. However, this could 
also apply to ex vivo approaches, where the gene-modified cells, still harboring viral membrane-derived 
proteins on their outer surface, are delivered to the patient. The viral membrane-derived proteins on the 
modified cells could potentially be recognized and eliminated by the recipient’s immune system. In 
summary,  alpharetroviral  particles  produced  in  human  suspension  cells  might  harbor  improved 
immunological safety characteristics as well as a higher potency in terms of transduction efficacy. 
Increasing demand for clinically applicable retroviral vector batches demonstrates the importance of 
economic vector production for future gene therapy trials. In contrast to transient vector generation,  
the use of stable packaging cell lines promises consistent, economic, large-scale vector production and 
thus potentially allows treatment of greater numbers of patients. The perspective of stable alpharetroviral 
SIN vector production together with several additional safety features, such as the lack of sequence 
overlap between the vector and the helper constructs as well as the general inability to replicate in 
mammalian  cells,  underline  the  potential  value  of  alpharetroviral  SIN  vectors  for  future  gene  
therapy approaches. 
5. From Bench to Bedside: Regulatory Requirements for Clinical Translation 
Gene therapy using retroviral vectors has proven to be very effective in several clinical trials targeting 
hematopoietic stem cells and T-lymphocytes. Previous trials primarily employed gammaretroviral  and 
lentiviral vectors, but the knowledge gained from experiences with these retroviral family members can 
be applied to advance new generation alpharetroviral SIN vectors to the clinical arena. 
Generally, regulatory agencies, e.g. the U.S. Food and Drug Administration (www.fda.gov) and the 
European  Medicines  Agency  (www.ema.europa.eu),  are  responsible  for  reviewing  and  approving 
planned gene therapy clinical trials. In light of previous severe adverse events, it is imperative to prove 
that the intended alpharetroviral gene therapy strategy is safe. To meet this goal, several recommendations 
for advanced therapy medicinal products (ATMP, a therapeutic product based on genes, cells or tissues) 
have been established (see recommendations on aforementioned webpages). For the regulatory review 
process of ATMPs, careful risk-benefit assessments need to be performed in the context of the particular 
clinical indication under study. This includes characterization of the alpharetroviral vector, such as 
content (including the transgene), delivery mode, and the somatic cell therapy product’s behavior in 
different contexts (e.g., isolated tissues and living organisms). Kaufmann et al. [87] provided a good 
example of validation of alpharetroviral gene therapy for a specific disease in a preclinical mouse model 
employing transduced mouse hematopoietic stem cells and, as a second step, in a humanized mouse 
model using alpharetrovirally corrected patient cells.  
In  general,  design  of  alpharetroviral  vectors  for  clinical  applications  should  comply  with  
replication-incompetence,  low  genotoxicity,  low  immunogenicity,  and  the  exclusion  of  germ-line 
integrations. Also the following points should be taken into account for the transgene and its product 
(see  FDA  guidelines):  (i)  preferably  localized  or  lineage-specific  expression  rather  than 
systemic/ubiquitous expression; (ii) low level and duration of expression (to avoid phenotoxicity); and Viruses 2014, 6  4824 
 
 
(iii) anticipation of acute vs. long-term effects. With respect to transgenes, especially growth factors, 
growth factor receptors [128] and immune modulators should be handled with care. 
There are basically two different ways to deliver therapeutic transgenes into patient cells—in vivo or 
ex vivo. While in vivo transgene delivery is relatively simple since it only requires the injection of 
purified virus into the target organ or into the bloodstream, it is associated with several concerns 
including toxicity, immunogenicity, lack of specificity and dose-control. In contrast, ex vivo transgene 
delivery is more complex. It requires isolation of the target cells, in vitro culture, and re-infusion after 
cell modification. However, ex vivo transgene delivery enables a tight control of specificity, vector dose, 
and circumvents human complement inactivation of retroviral particles. As for alpharetroviral gene 
therapy, the ex vivo method is thus preferred.  
Preclinical investigation cannot be applied directly to patients because of regulatory requirements 
(except  for  the  “hospital  exemption  clause/compassionate  use”)  and  ethical  concerns.  Therefore, 
appropriate animal models have to be chosen, which should ideally be biologically relevant and should 
model the disease phenotype. In the case of a specific monogenetic disease, the corresponding knock out 
models should be used. Ideally, also the transplantation of patients’ cells in so called “humanized” mouse 
models,  which  accept  human  grafts,  e.g.,  the  NOD/Prkdcscid/Il2rg  (NSG)  knock  out  model,  should  
be performed. 
Candidate target cells for clinical application include human CD34+ hematopoietic precursor cells 
and T cells. Both cell types can be efficiently transduced with alpharetroviral vectors, as demonstrated 
by our group [60] (and unpublished data). Moreover, Kaufmann et al. [87] showed efficient transduction 
of X-linked chronic granulomatous disease (CGD) patient derived CD34+ cells with an alpharetroviral 
vector  expressing  a  functional  version  of  the  defective  gene.  Importantly,  upon  transplantation  of  
the gene-modified cells into the NSG mouse model, they demonstrated functional disease correction and 
long-term expression of the transgene without obvious side effects. Interestingly, no aberrant splicing, 
caused by interference of viral and cellular splice sites, was observed for alpharetroviral in contrast to 
lentiviral vectors, implying that the safety profile of alpharetroviral vectors may even extend beyond 
their more neutral integration pattern in clinically relevant human CD34+ cells [61,87].  
In  addition,  some  overall  safety  considerations  of  alpharetrovirally  genetically  modified  
cells  as  somatic  cell  therapy  medicinal  products  need  to  be  addressed  in  vivo.  This  includes  
the  analysis  of  (i)  biodistribution  and  toxicology  (to  identify  potential  sites  of  toxicity),  
(ii)  immuno-toxicity/immunogenicity  (vector/transgene  products  affecting  the  immune  system,  
pre-exisiting immunity and cross-reactivity) and (iii) shedding issues of retroviral vectors [129]. Ideally, 
most analyses should be accomplished with the clinical vector production lot and, if possible, in a 
controlled environment and in GMP-like compliance.  
6. Potential Future Clinical Applications of Alpharetroviral SIN Vectors 
The use of gammaretro- and lentiviral vectors enabled several gene addition strategies in clinical trials 
targeting human hematopoietic stem cells and T-lymphocytes. In these trials, retroviral transduction was 
performed ex vivo followed by transplantion of genetically engineered cells into patients suffering from 
inherited  diseases,  e.g.,  from  severe  combined  immunodeficiency  [130–132],  Wiskott-Aldrich  
syndrome  [24,133],  chronic  granulomatous  disease  [19,20],  adrenoleukodystrophy  [134]  and Viruses 2014, 6  4825 
 
 
metachromatic  leukodystrophy  [135],  or  from  cancer  (examples  below).  While  some  of  the  gene 
therapies were quite effective, side effects related to insertional transformation were also observed  
(see  Section  3.2).  These  adverse  events  were  primarily  related  to  the  first  generation  LTR-driven 
gammaretroviral vector architecture and the use of hematopoietic stem cells, which are more prone for 
insertional transformation than other cell types. Since the integration pattern can also influence the 
likelihood of insertional transformation, more randomly integrating vectors represent potentially safer 
tools  for  future  gene  therapy  trials.  Generally,  we  foresee  three  main  arguments  for  the  use  of 
alpharetroviral vectors in clinical translation. (i) The aforementioned potentially safer and more random 
integration  pattern  that  could  provide  a  lower  risk  of  insertional  mutagenesis;  (ii)  a  clean  vector 
architecture,  not  only  lacking  viral  enhancer,  promoter  and  splice  elements,  but  also  viral  coding 
sequences, which can potentially contribute to immune responses as observed in patients treated with  
ex  vivo-engineered  T-cells,  leading  to  limited  peripheral  persistence  [72,73];  and  (iii)  the  stable 
packaging cell line production perspective for alpharetroviral vectors associated with an economic and 
consistent production of larger virus batches, as needed for treatment of higher number of patients or to 
deliver greater numbers of modified cells per patient.  
Relatively high cell numbers are needed for a number of T cell applications. Given the efficient 
transduction of primary T cells and the stable production perspective, alpharetroviral vectors are ideal 
tools for genetic modification of primary T cells, which is why we elaborate on the potentially promising 
applications here. T cells can be easily purified from the peripheral blood and have thus been a promising 
target for genetic modification for almost 25 years. The first trial of genetically modified T cells was 
performed  by  Rosenberg  and  coworkers  [136],  who  demonstrated  gammaretroviral  transduction  of  
tumor-infiltrating lymphocytes. During the past two decades, numerous promising trials with genetically 
modified T cells were initiated, taking advantage of antigen-specific (i) T cell receptors (TCRs) and  
(ii) chimeric antigen receptors (CARs) as well as (iii) suicide gene approaches.  
(i) In the TCR approach, T cells recognize tumor peptides by specifically isolated tumor-specific 
TCRs. Gammaretroviral vectors were introduced into T cells to encode the α and β TCR chains forming 
a TCR specific for the melanoma antigen MART1 [137], CEA (for colorectal carcinoma), NY-ESO-1 
(melanoma), WT1 (leukemia), and CMV pp65 (for EBV treatment) [138–140].  
(ii) Furthermore, T cells can be engineered to express a chimeric antigen receptor (CAR) comprising 
an extracellular single chain-antibody (scFv) linked to an intracellular CD3ζ domain (and optionally 
further co-stimulatory domains). In comparison to conventional TCRs, CARs are not HLA-restricted or 
dependent on antigen  presentation. As for TCRs,  a larger list of potential tumor  targets has been 
developed [141] and corresponding scFv are available. Also, next generation CARs were developed 
exploiting new transmembrane domains and other co-stimulatory domains (e.g., CD28, 4-1BB) [142]. 
CAR-T cells have shown remarkable results in B cell malignancies [143–145] and neuroblastoma [146]. 
(iii) Another interesting avenue is T cell engineering with suicide genes, as in the clinical setting to 
control graft vs. host disease (GvHD). Several trials have documented the feasibility of the HSV TK 
(thymidine kinase) to serve as a suicide gene, which converts the clinically approved prodrug Ganciclovir 
into  a  toxic  substance  [147,148].  Recently,  a  chemically  inducible  safety  switch,  the  inducible  
caspase 9 (iCasp9), was developed and proved to be very effective, eliminating >90% of modified  
T cells within 30 min after administration and resolving the GvHD without recurrence [149].  Viruses 2014, 6  4826 
 
 
Interestingly and arguing in favor of further clinical trials, T cell applications seem to have a lower 
propensity for insertional transformation. Genetically engineered T cells (transduced by a gammaretroviral 
LTR-driven vector) were followed in patients for over 10 years without any overt genotoxicity or 
evidence of transformation [150]. This favorable risk assessment is also in  agreement with recent 
evidence from mouse models showing a relative resistance of mature T cells to insertional transformation 
by retroviral vectors and even known T cell oncogenes [151,152]. Nevertheless, specific conditions have 
been described that caused insertional transformation in T cells [153]. In this regard, the more neutral 
integration pattern of alpharetroviral SIN vectors is expected to further decrease the likelihood of adverse 
events related to insertional mutagenesis.  
In  addition  to  gene-addition  strategies  as  discussed  above,  gene  correction  or  gene  disruption 
strategies,  allowing for site-specific  genome  editing, can also be of great therapeutic value. Here, 
integrating and non-integrating alpharetroviral vectors could be useful for delivery of the required 
components to the target cell. Emerging technologies for site-specific genomic editing include Zinc 
finger  nucleases,  transcription  activator-like  effector  nucleases,  and  the  CRISPR/Cas9  system.  
These technologies exploit designer nucleases, which are relatively large or have to be used as pairs. 
Therefore, the theoretically large coding capacity of alpharetroviral vectors could be beneficial.  
In  summary,  several  useful  applications  for  gene  therapy  have  been  recently  developed  using 
gammaretro- and lentiviral vectors for genetic modification of hematopoietic cells. Given the more 
random  and  potentially  safer  integration  pattern,  the  clean  vector  architecture  and  the  stable  
packaging perspective, several potential alpharetroviral vector applications could be envisioned for 
future clinical use. 
7. Conclusions and Outlook 
Alpharetroviruses were discovered more than 100 years ago. However they have come into play as 
potential retroviral vectors for human gene therapy only very recently, when serious adverse events in 
clinical trials underscored the need for safer vectors. Intensive research efforts revealed that retroviral 
vector genotoxicity is largely influenced by the vector architecture and the integration pattern. Thus, 
alpharetroviral vectors, which have a relatively neutral integration pattern compared to clinically used 
gammaretroviral and lentiviral vectors, represent attractive and potentially safer tools for human gene 
therapy. We applied the latest concepts of retroviral vector design to develop state-of-the-art alpharetroviral 
SIN  vectors  with  a  split-packaging  design.  Proof-of-principle  for  these  vectors  was  provided  by  
the genetic modification of clinically relevant target cells, such as hematopoietic stem and progenitor 
cells  and  T-lymphocytes.  Moreover,  future  incorporation  of  supporting  transcriptional  regulatory 
elements protecting from cellular silencing mechanisms is likely to further enhance the therapeutic 
potential  of  alpharetroviral  vectors.  Since  upscaling  retroviral  vector  production  represents  one  of  
the major challenges on the road to clinical translation, it is especially promising that alpharetroviral SIN 
vectors can be produced transiently as well as from stable human packaging cell lines. Compliance with 
several regulatory requirements, including performance of preclinical biodistribution and toxicology 
studies of the gene therapy product and careful risk-benefit assessments are still needed to further 
advance alpharetroviral vectors to the clinical arena. Altogether, the reduced genotoxicity in combination 
with the perspective of economic, stable vector production underlines the potential of alpharetroviral Viruses 2014, 6  4827 
 
 
SIN vectors as useful tools for future human gene therapy strategies. Thus, as paradoxical as it seems, a 
viral genus, first noted for its transforming potential, might contribute to safer human gene therapy in 
the near future. 
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